FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES II	N BENEFICIAL	<b>OWNERSHIP</b>
O I / (I E I I I E I I I	0. 0.17.110201	T DEITE TONCE	O 1111121101111

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
houre por rosponso	. 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Peterson Amy C.				2. Issuer Name <b>and</b> Ticker or Trading Symbol  CytomX Therapeutics, Inc. [ CTMX ]						(Ch	eck all applic	,		on(s) to Issu 10% Ow Other (s	ner		
(Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400				3. Date of Earliest Transaction (Month/Day/Year) 02/14/2020								X Officer (give title Officer Specify below)  EVP, Chief Development Officer					
(Street) SOUTH FRANCI	ISCO C.		94080 (Zip)	4.	If Ame	ndment, I	Date	of Original Fi	iled (I	Month/Da	y/Year)	Line	X Form f	iled by One iled by More	Repo	rting Persor	ı
1. Title of Security (Instr. 3) 2. Transac			Transactio	action 2A. Deemed Execution Date,			r) Code (Instr. 5)			ed (A) or tr. 3, 4 and	5. Amou Securitie Beneficia Owned F	nt of 6. Over s (D) of (I) (Ir		Direct of Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date, curity   or Exercise   (Month/Day/Year)   if any		Code	ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$7.13	02/14/2020		A		25,000		(1)	02	/13/2030	Common Stock	25,000	\$0.00	25,000		D	

## **Explanation of Responses:**

1. 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

/s/ Lloyd Rowland, as

02/19/2020 Attorney-in-Fact for Amy C.

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.